Pfizer's US $830 million cooperation in the development of new protein degradation therapy

Source: yaomingkant January 5, 2018 arvinas announced today that it has signed a research cooperation and license agreement with Pfizer to use arvinas proprietary protac (proteolysis targeting chimeras) platform to discover and develop small molecular therapies that can degrade pathogenic cell proteins Arvinas is a biotechnology company focused on the development of new drugs based on protein degradation Based on the innovative research of Dr Craig crews, founder and chief scientific consultant of the company, at Yale University, arvinas is transforming natural protein degradation methods into new drugs for treating cancer and other diseases Its proprietary protac based drug development platform uses ubiquitin proteasome system to induce protein degradation rather than protein inhibition, and provides potential advantages for proteome "non pharmaceutical" and "pharmaceutical" components This has greatly expanded the ability to manufacture drugs for many new, previously inaccessible targets Arvinas's own pipeline development focuses on androgen and estrogen receptor degradation for prostate and breast cancer Last November, it named arv-110, the first clinical candidate drug that targets and induces androgen receptor protein degradation Last December, arv-378, the second candidate drug targeting and inducing the degradation of estrogen receptor protein, was named The multi-year agreement between arvinas and Pfizer covers the discovery and development of potential clinical candidates for protac, which aims to degrade several key pathogenic proteins in multiple therapeutic fields Under this cooperation, arvinas will strive to promote new drug discovery, and Pfizer will be responsible for the clinical development and commercialization of any products produced by the cooperation Under the terms of the agreement, arvinas will receive up to $830 million in upfront payments and potential development and commercialization milestone payments In addition, arvinas will be entitled to royalties for global sales of any products resulting from this collaboration "As a global industry leader, Pfizer has a unique position to work with us to develop the potential of protocs in multiple disease areas," said Dr John Houston, President and CEO of arvinas "This marks another key milestone, as we continue to expand the use of our target protein degradation platform and drive arvinas's first drug candidates into clinics ”"Protein degradation is an area of great interest to us, and we look forward to working with arvinas to determine the potential applicability of this approach in multiple therapeutic areas," said Dr John Ludwig, director of pharmaceutical science at Pfizer.